CreatorsPublishersAdvertisers
View more in
Medical & Biotech

Precision BioSciences, iECURE Ink Licensing Pact For Gene Editing Therapies

Benzinga
Benzinga
 2021-09-09
Cover picture for the article

Precision BioSciences Inc (NASDAQ: DTIL) and iECURE announced a license and collaboration agreement. Under the agreement iECURE plans to advance Precision's PBGENE-PCSK9 candidate into Phase 1 studies and gain access to Precision's...

www.benzinga.com

Comments / 0

Comments / 0